Suven Life Sciences Ltd
Suven Life Sciences Ltd Company History
Suven Life Sciences is a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of novel therapeutics for the treatment of neurodegenerative disorders. The goal is to be the leading biopharmaceutical company focused on the treatment of dementia, a condition characterized by a significant decline in mental capacity and impaired daily function. The Company is targeting Central Nervous System (CNS) indications where there is a high unmet medical need, growing patient populations and with possible commercialization options. Suven has a wholly owned subsidiary, Suven Neurosciences, Inc., USA, focused on clinical development activities of Suven molecules from phase 2, Proof-of-Concept (POC) studies
2000
The Company has entered into agreement with NSDL and CDSL for dematerialisation of shares.
Company bags export orders of Rs 21 cr
2001 - Borregaard Industries Ltd, Norway, acquires 15% stake in the company
2002- An accident occurred at the company's Suryapet Unit AS when a transporters vehicle entered the factory premises on November 17, 2002
Pfizer Ltd and Suven Pharmaceuticals Ltd have tied up with the Bombay College of Pharmacy to set up an academy for clinical excellence (ACE) , in Mumbai.
2003-Borregaard Industries Ltd, a Norwegean pharma player has offloaded its entire 17.05 per cent stake ( 7.50 lakh equity shares) in Suven Life Sciences Ltd
Suven Life Sciences USA LLC a wholly owned subsidiary of Suven Pharmaceuticals Ltd has acquired Synthon Chiragenics Corporation New Jersey USA
2000
2004
Suven Life Sciences Ltd has informed the stock exchanges that its shareholders at the extraordinary general meeting held on Jan 05 have approved the sub-division of equity shares into face value of Rs 2 each from the face value of Rs 10 each.
Suven Life Sciences BoD approves preferential shares issue
Suven Life Sciences Ltd has said that its board of directors on Jan 19 has allotted 30 lakh equity shares of face value of Rs 2 each on preferential basis to four investors. While Emerging Markets Management LLC was allotted 10 lakh shares, Aeneas Portfolio Company LP 8.75 lakh shares, Commonwealth Equity Fund Ltd, a sub-account of Batterymarch Financial Management Inc, 6.25 lakh shares and Mr Rambabu Chirumamilla was given 5 lakh shares.
Two units of Suven Life (Suryapet & Jeedimetla) get ISO confirmation
2004
2007
Suven Life Sciences Ltd (Suven) on November 27, 2007 has announced that the European Patent Office (EPO) granted Two Patents, 1523486 and 1581538 to Suven and are valid until June 2022.
The Company has issued Bonus Shares in the Ratio of 1:1.
The Company has splits its face value from Rs2/- to Rs1/-.
2007
2009
Suven Life Sciences has secured two U.S. patents relating to new chemical entities (NCEs) for treatment of disorders associated with neurodegenerative diseases
Suven Life Sciences Ltd (Suven) announces today that the European Patent Office (EPO) has Issued 3 new Patents: EP1537113, EP1704154 and EP1856132 corresponding to three New Chemical Entities (NCEs) for the treatment of disorders associated with Neurodegenerative diseases and these Patents are valid until 2022,23 and 24 respectively.
2009
2010
Suven Secures Two product patents in China and Russia
Suven Life Sciences secures 5th Product Patent from US patent office for their NCE to treat Central Nervous System
Suven Life Sciences bagged the eight product patent from European Patent Office (EPO) for their NCE to treat Central Nervous System (CNS) disorders.
Suven Life Secures Three Australian Patents on NCEs
Suven gets two patents from Japanese Patent Office for NCE's
2010
2011
Suven's Unit-III receives US FDA Acceptance
Suven Life Sciences secures 7 Product Patents for their NCEs in several key markets in the world
Suven Life Sciences bags "Bio-Excellence Award at Bangalore India Bio 2011
Suven Life Sciences secures 2 Product Patents for their NCEs in the key markets in the world
Suven Life Sciences bags Pharmexcil's Gold "Patent Award"
2011
2012
Suven Life Sciences secures 3 Product Patents for their NCEs in Mexico and USA
Suven Life Sciences gets 4 Product Patents in Japan, Australia, Europe and Eurasia
Suven Life Sciences bags Pharmexcil's "Platinum Patent Award"
Suven Life Sciences secures 5 Product Patents for their NCEs in China & Korea.
2012
2013
Suven Life Sciences bags 4 Product Patents for their NCEs in China, Mexico and New Zealand"
Suven Life secures three Product Patents for their NCEs in Canada and Eurasia"
Suven Life secures two (2) Product Patents for their NCEs in Europe
The Company has recommended Dividend Re. 30 paisa per equity share of face value of Re. 1/-.
2013
2014
SUVENÂS PASHAMYLARAMÂS UNIT RECEIVES US FDA ACCEPTANCE
Suven Life Sciences bags PharmexcilÂs 'Gold Patent Award' for NCEÂs and 'Outstanding Export Performance Award' for Contract Research and Manufacturing.
Suven Life Sciences awarded Forbes Asia's "Best Under A Billion" Award
2014
2015
Suven initiated Multiple Ascending Dose (MAD) studies in Phase 1 clinical Trial for their investigational compound SUVN-G3031
Suven Life Sciences bags PharmexcilÂs Gold Patent Award
2015
2016
Suven Life Sciences gets product patent for NCEs.
Suven Life Sciences secures two (2) Product Patents in Europe and Israel.
2016
2017
"Suven Life Sciences secures Product Patents in Canada and India".
"Suven Life Sciences secures Product Patents in Eurasia and Norway".
Suven bags product patent for treatment of neuro diseases.
2017
2018
"Suven Life Sciences secures Product Patents in Brazil andEurasia".
"Suven Life Sciences secures Product Patents in Australia andHong Kong".
2018
2019
"Suven completes the purchase of assets of Rising Pharmaceuticals through its joint venture partner, Shore Suven Pharma Inc.".
"Suven Life Sciences secures Product Patents in Australia and Singapore".
2019
2022
Company issued rights shares of Rs. 1 in the ratio of 1:2 at a premium of Rs. 54 per share.
2022
